ModifiedPremera BluecrossPolicy N/A

Nulojix (belatacept) for Adults

Medical necessity and site-of-service criteria for use of Nulojix (belatacept) in adults for prophylaxis of organ rejection, primarily for kidney transplant recipients, including documentation, coding, and evidence considerations; applies to Premera members except where noted for Alaska fully-insured members.

Policy Summary

PayerPremera Bluecross

PolicyNulojix (belatacept) for Adults

Policy CodePolicy N/A

Change TypeMaterial operational and clarification updates (approval duration, site-of-service exceptions, therapeutic substitution)

Effective DateJun. 1, 2026

Next Review Date

Key ActionObtain prior authorization with documentation; initial approvals for Nulojix (belatacept) are issued for up to 12 months.

SourceLink

POLICY UPDATE CHANGES

Site of Service Medical Necessity criteria does not apply to Alaska fully-insured members pursuant to Alaska HB 226.

Length of initial approval for Nulojix (belatacept) updated from 6 months to 12 months.

Exception to the site-of-service requirements added for certain individuals receiving treatment for cytokine release syndrome (CRS).

Azathioprine can be used for individuals who have tried and did not tolerate mycophenolate mofetil (MMF).

Updated Nulojix (belatacept) length of initial approval from 6 months to 12 months.

18+minimum age for therapeutic coverage

EBV+ requiredserostatus requirement

J0485

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 moinitial approval length

Higher rejectionconversion risk

Coverage Criteria for Nulojix (belatacept)

Induction therapy (kidney transplant)

Covered when ALL of the following are met:

Induction: adult kidney transplant: Individual is aged 18 years or olderage >=18

Supported by policy medical necessity criteria

Induction: EBV serostatus: Individual has Epstein-Barr Virus (EBV) seropositive test resultEBV seropositive

EBV seropositive required to avoid increased PTLD risk

Induction: concomitant agents: Nulojix (belatacept) is used in combination with ALL of the following: basiliximab (Simulect), mycophenolate mofetil (MMF) (azathioprine acceptable if MMF not tolerated), and corticosteroidsconcurrent basiliximab + MMF (or azathioprine if intolerance) + corticosteroids

Per manufacturer-recommended regimen for induction

Maintenance therapy (kidney transplant)

Covered when ALL of the following are met:

Maintenance: adult kidney transplant: Individual is aged 18 years or olderage >=18

Policy age requirement for coverage

Maintenance: EBV serostatus: Individual has Epstein-Barr Virus (EBV) seropositive test resultEBV seropositive

EBV seropositive required to avoid increased PTLD risk

Maintenance: concomitant agents: Nulojix (belatacept) is used in combination with mycophenolate mofetil (MMF) (azathioprine acceptable if MMF not tolerated) and corticosteroidsconcurrent MMF (or azathioprine if intolerance) + corticosteroids

Investigational / not recommended indications

Not covered or considered investigational:

Other organs: Use of Nulojix (belatacept) for prophylaxis of organ rejection in transplanted organs other than kidney is considered investigationalN/A

Policy statement labels non-kidney prophylaxis investigational

Pediatrics: Use in individuals under 18 years of age is considered investigationalage <18

No studies supporting pediatric use per policy

Liver transplant: Use in liver transplant individuals is not recommended by the manufacturer due to increased risk of graft loss and deathN/A

Clinical evidence and coverage considerations

Evidence and policy guidance relevant to coverage decisions:

Efficacy: Randomized trials (phase II and III BENEFIT/BENEFIT-EXT) demonstrated higher mean cGFR/eGFR with belatacept versus cyclosporine and comparable patient and graft survival at follow-up periods up to multiple years.Trial results (see cited RCTs)

cGFR advantages reported in phase II (≈+8.8 mL/min) and BENEFIT-EXT (≈+11 mL/min)

Safety cautions: Belatacept is associated with opportunistic infections, increased PTLD (particularly in EBV seronegative individuals), tuberculosis in some studies, infusion-related reactions, and rare PML; monitor accordingly.Clinical vigilance and monitoring

Safety signals summarized from evidence review and trials

Conversion risk: Conversion from a calcineurin inhibitor (CNI)–based maintenance regimen to belatacept increases the risk of acute rejection and is not recommended unless the individual is CNI intolerant.

General Coverage Conditions

Coverage is conditional on meeting medical necessity and site-of-service criteria, following FDA prescribing information and any state-specific exceptions:

General conditions: Treatment must follow the product's FDA dosing and administration; prior authorization is required; medical necessity criteria for the infusion drug must be met.Initial approval up to 12 months

Site-of-service criteria and state exceptions (e.g., Alaska HB 226), CRS exception, and access-related exceptions (no infusion center within 50 miles or no contracted home infusion) are described in policy history and operational guidance

This policy does not apply to members who are currently admitted to an acute hospital inpatient setting. Site-of-service medical necessity reviews described in this policy apply only to outpatient medical benefit settings (e.g., infusion center, physician office, home infusion) and do not affect inpatient care determinations.

Prior iterations of this policy referenced non-formulary exception reviews; those references have since been removed. Operationally, non-formulary exception language was revised during recent updates and the policy history documents the removal of the non-formulary exception review reference while retaining the prior authorization and formulary processes now described in the policy.

This medical policy does not apply to Medicare Advantage. Coverage determinations remain subject to the limits and conditions of the member's contract; providers and members should consult the member benefit booklet or contact Member Services for plan-specific coverage details.

Use of Nulojix (belatacept) in individuals who are EBV seronegative or have unknown EBV serostatus is contraindicated because EBV seronegativity is associated with an increased risk of post‑transplant lymphoproliferative disorder (PTLD). Providers must document EBV seropositive status to meet medical necessity criteria.

Conversion of a stable kidney transplant recipient from a calcineurin inhibitor (CNI)–based maintenance regimen to belatacept is not recommended unless the individual is intolerant of CNI therapy; randomized studies have shown increased rates of acute rejection after conversion, particularly during the first year post-conversion.

This policy is intended as a clinical guide for evaluating medical necessity for Nulojix (belatacept). Actual coverage depends on the member's benefit plan, applicable contract terms, and any state-specific exceptions; always verify benefits in the member benefit booklet or with Member Services prior to ordering therapy.

Candidate Criteria and Regimen Considerations

Kidney transplant candidate criteria for belatacept

Kidney transplant-specific candidate requirements:

Candidate: age: Recipient is aged 18 years or olderage >=18

Adult-only indication for coverage

Candidate: EBV serostatus: Recipient must be Epstein-Barr Virus (EBV) seropositiveEBV seropositive

EBV seronegative or unknown status is contraindicated due to increased PTLD risk

Kidney transplant candidate and regimen considerations

Evidence from kidney transplant trials and regimen considerations:

Contraindications

Use of Nulojix (belatacept) in individuals who are EBV seronegative or with unknown EBV serostatus is a contraindication due to an increased risk of post‑transplant lymphoproliferative disorder (PTLD); such use is considered not medically necessary under this policy and requires documentation of EBV seropositive status for approval.

The manufacturer does not recommend use of Nulojix (belatacept) in liver transplant recipients because post‑marketing and study data have shown an increased risk of graft loss and death in this population; therefore liver transplant use is not recommended by the manufacturer and is considered outside routine coverage.

Key safety cautions include an increased risk of post‑transplant lymphoproliferative disorder (PTLD), particularly in EBV seronegative individuals, opportunistic infections (including higher rates of some fungal infections compared with tacrolimus), and rare reports of progressive multifocal leukoencephalopathy (PML). These risks are discussed in the evidence review and reflected in prescribing information and the policy's contraindication language.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required and Approval Duration

Prior authorization is required for Nulojix (belatacept). Initial approvals may be granted for up to 12 months. Reauthorizations may be granted for up to 12 months when drug-specific coverage criteria are met and chart notes demonstrate continued positive clinical response.

Initial approval duration: up to 12 months
Re-authorization: up to 12 months with documentation of continued benefit
Requests exceeding these durations or not following FDA dosing/administration may be denied

Denial Risk

EBV Serostatus Contraindication and Denial Risk

Nulojix is contraindicated for use in individuals who are EBV seronegative or whose EBV serostatus is unknown due to increased risk of post-transplant lymphoproliferative disorder (PTLD). Providers should confirm and document EBV serostatus prior to initiation; use in EBV seronegative or unknown serostatus may result in denial.

Coding and Billing

HCPCSHCPCS

J0485

Injection, belatacept (Nulojix), 1 mg

Covered HCPCS CodesHCPCSCovered

J0485

Belatacept (Nulojix) HCPCS code

HCPCS codes referenced in policy historyHCPCS

J0485	Belatacept (per document history: HCPCS code added 1/1/13)
C9286	Deleted effective 12/31/12 (per policy history)
J3490	Non-specific code removed (per history)
J3590	Non-specific code removed (per history)
J7599	Non-specific code removed (per history)

Site-of-service age threshold

Site-of-service age threshold>= 13 years for site-of-service review

RationalePediatric infusion considerations (physiology, dosing, equipment, behavioral management) inform threshold

Applies toLocation-based site-of-service medical necessity reviews (hospital outpatient, infusion center, physician office, home)

cGFR difference

Phase II (Year 2) mean cGFR advantage+8.8 mL/min (mean change from baseline: belatacept +8.8 mL/min vs CNI +0.3 mL/min)

BENEFIT-EXT (3-year) cGFR difference~+11 mL/min higher mean cGFR with belatacept versus cyclosporine

Evaluation and Documentation Requirements

Documentation Required

Evaluation requirements: document transplant type, EBV serostatus, meds, and H&P

Medical record documentation must include the transplant type, EBV serostatus, concurrent medication use, and a relevant history and physical exam to support coverage determinations.

Note

Additional evaluation requirements not specified

Additional evaluation requirements are not specified in the provided source window.

Site and Center Requirements

Note

Site-of-service reviews apply to outpatient infusion settings; center accreditation not specified

Site-of-service reviews apply to outpatient infusion settings; specific accreditation or volume requirements for centers are not specified in this portion of the policy.

Site-of-service rules may not apply to Alaska fully‑insured members per Alaska HB 226.

Note

Center requirements not specified

No additional center requirements are specified in the provided source window.

Maintenance Infusions and Follow-up Coverage

Maintenance belatacept infusion

Reauthorization requirementReauthorization requires meeting drug-specific coverage criteria and chart notes documenting continued positive clinical response to therapy

Approval durationInitial and reauthorization approvals may be granted for up to 12 months when criteria met

Documentation neededChart notes must demonstrate continued clinical response to justify maintenance infusions

maintenance immunosuppression with belatacept

Durable renal benefit in trialsRandomized trials and long-term follow-up show higher GFRs with belatacept vs cyclosporine and comparable graft/patient survival

Safety monitoringMonitor for opportunistic infections, PTLD, tuberculosis, infusion reactions, and rare PML observed in trials

Definitions and Abbreviations

Mechanism of action

Primary mechanismBelatacept binds CD80 and CD86 on antigen-presenting cells to block CD28 co-stimulation of T cells

Downstream effectInhibits T-lymphocyte proliferation and reduces production of interleukin-2, interferon-?, and TNFα

Clinical rolePrevents T-cell–mediated immunologic rejection in kidney transplant recipients

PTLD risk

PTLD associationBelatacept has a black box warning for post-transplant lymphoproliferative disorder (PTLD) observed in trials

Risk factorsGreater risk in Epstein-Barr virus (EBV) seronegative recipients and those previously treated with T-cell depleting therapies

Background and Rationale

Nulojix (belatacept) is a CTLA‑4–Ig fusion protein that inhibits T‑lymphocyte activation by binding CD80/CD86 on antigen-presenting cells and blocking CD28 co‑stimulation. It is used as an IV immunosuppressive agent for prevention of kidney transplant rejection as induction and maintenance therapy; trials demonstrated higher mean GFRs versus cyclosporine with comparable long‑term graft and patient survival but increased rates of some early acute rejection episodes. Safety considerations include the boxed warning for PTLD and other opportunistic infections.

Policy Revision History

2012-02-27policy_created

New policy established and added to Prescription Drug section; reviewed by P&T January 24, 2012.

2013-02-13update

Policy replaced after literature review; added HCPCS code J0485 (effective 01/01/2013) and removed C9286 (deleted 12/31/2012).

2014-03-25update

Policy replaced following literature review with no change to policy statement.

Policy Summary

PayerPremera Bluecross

PolicyNulojix (belatacept) for Adults

Policy CodePolicy N/A

Change TypeMaterial operational and clarification updates (approval duration, site-of-service exceptions, therapeutic substitution)

Effective DateJun. 1, 2026

Next Review Date

Key ActionObtain prior authorization with documentation; initial approvals for Nulojix (belatacept) are issued for up to 12 months.

SourceLink

On This Page

Per maintenance regimen in policy

Approval duration: Initial and reauthorization approvals may be granted for up to 12 months when criteria are met and clinical response is documented<=12 months per authorization

Authorization length per policy

Manufacturer recommendation cited in package insert and policy

Clinical judgment; document CNI intolerance to convert

Added to prescribing information and policy evidence review

Therapeutic substitution: Azathioprine may be used for individuals who have tried and did not tolerate mycophenolate mofetil (MMF).Tolerability documented in chart

Policy update added 2023 allowing azathioprine when MMF intolerant

De novo kidney transplant use: Belatacept-based regimens demonstrated renal-sparing benefits (higher cGFR) and comparable graft and patient survival versus cyclosporine in de novo kidney transplant recipients in randomized trials.Trial-based evidence

Phase II and BENEFIT/BENEFIT-EXT results support de novo use in adults

Maintenance considerations: Long-term follow-up shows durable renal benefit; however, monitor for PTLD, tuberculosis, and opportunistic infections; conversion studies show increased early rejection risk when switching from CNIs.Ongoing monitoring required

Balance renal benefit with safety profile when selecting regimen

Document EBV serostatus in the chart prior to therapy
Requests for EBV seronegative or unknown-status individuals are contraindicated and may be denied

Note

Inpatient Admission Exclusion

This policy does not apply to members who are currently admitted to an acute hospital setting. Review and authorization for inpatient administrations should follow inpatient admission rules.

Policy exclusion: active acute hospital admission

Documentation Required

Documentation to Support FDA Dosing and Site-of-Service Exceptions

Documentation submitted must support use consistent with the FDA dosing and administration prescribing information and any site-of-service exceptions. Medical records should demonstrate that medical necessity criteria are met.

Include documentation supporting FDA-consistent dosing and any requested site-of-service exception
Noncompliance with FDA dosing or exceeding specified approval duration may lead to denial

Billing Rule

Dosing Authority — Follow Prescribing Information

Providers must follow the Nulojix (belatacept) prescribing information for dosing and administration. Requests that do not follow the product's FDA dosing recommendations may be denied.

Follow current Nulojix prescribing information for dose, frequency, and administration

Prior Authorization

Concomitant Therapy Requirement

Nulojix must be used in combination with specified concomitant immunosuppressants for approved indications. For initial maintenance and post-induction therapy in kidney transplant recipients, Nulojix is used with mycophenolate mofetil (MMF) and corticosteroids and (for induction) basiliximab where specified.

Required concomitant agents: mycophenolate mofetil (MMF) and corticosteroids
Induction regimen includes basiliximab (Simulect) as specified

Step Therapy

Therapeutic Substitution and Step Sequencing (Azathioprine after MMF Intolerance)

Azathioprine may be used as an alternative anti-proliferative agent for individuals who have tried and did not tolerate mycophenolate mofetil (MMF). This therapeutic sequencing (MMF preferred; azathioprine acceptable after documented intolerance) must be documented in the medical record.

Therapeutic sequence: try MMF first; if not tolerated, document intolerance to MMF to support azathioprine use
Include chart notes documenting MMF trial and intolerance

Documentation Required

Required Medical Record Documentation

The individual's medical records must document that medical necessity criteria are met. At minimum, include office visit notes that document the type of transplant, EBV serostatus, concurrent medication use, and relevant history and physical examination findings.

Required documentation: transplant type, EBV serostatus, concurrent meds, history and physical, and ongoing response to therapy for re-authorization

Clinical implicationBelatacept regimens demonstrated durable renal-sparing benefit vs cyclosporine in trial follow-up

site of service distance

Site-of-service distance criterionNo outpatient infusion center within 50 miles may justify site-of-service exception

Related operational noteException also applies if there is no contracted home infusion agency that will travel to the patient's home or hospital is the only place offering infusion

History basisClarified in policy history (11/01/17 entry) to address access-related exceptions

Conversion cautionConversion from CNI to belatacept increases acute rejection risk and is not recommended unless CNI intolerant

Nulojix (belatacept) infusions

Indication contextNulojix (belatacept) used for induction and maintenance immunosuppression in kidney transplant per FDA prescribing information

Documentation requirementUse, dosing, and administration must follow the product's FDA prescribing information and be supported in submitted documentation

Authorization lengthInitial approvals and reauthorizations for Nulojix are issued for up to 12 months per policy updates

TimingMany PTLD cases occurred early (first 18 months) in trial follow-up

Calculated/estimated glomerular filtration rate

DefinitionCalculated/estimated glomerular filtration rate (cGFR/eGFR) — trial-reported measure of renal function used to compare belatacept vs CNIs

Trial relevancecGFR was the primary renal function metric showing higher values with belatacept in Phase II and BENEFIT-EXT studies

UnitsReported in mL/min (e.g., +8.8 mL/min, +11 mL/min differences)

Post-transplant lymphoproliferative disorder

AbbreviationPTLD = Post-transplant lymphoproliferative disorder

Clinical significancePTLD is a principal safety concern associated with belatacept use in trials

Implication for eligibilityEBV seropositive status required to avoid contraindication for belatacept

Site-of-Service

DefinitionSite-of-Service: the location where the drug is administered (hospital-based outpatient, infusion center, physician office, or home)

Medical necessity reviewSite-of-Service Medical Necessity criteria determine coverage for infusion drugs and may include age, distance, and access exceptions

Exceptions and state lawPolicy notes state-specific exceptions (e.g., Alaska fully-insured members per HB 226) and access exceptions such as CRS or >50-mile distance

2015-08-11annual_review

Annual review conducted; literature search found no studies requiring policy changes and non-specific HCPCS codes J3490, J3590, and J7599 were removed leaving J0485 as the specific code on the policy.

2016-06-01annual_review

Annual review approved May 10, 2016; 'Site of Service' criteria were added and the Policy section reformatted to include a tabulated medical necessity criteria view.

2016-11-01interim_review

Interim review approved October 11, 2016 clarifying that site-of-service review applies to those age 13 and older while drug criteria review applies to all ages.

2017-01-01interim_review

Interim review approved December 13, 2016 added 'Consideration of Age' requirements to the policy.

2017-09-25policy_statement_added

Policy statement added noting Nulojix (belatacept) is investigational for pediatric patients due to lack of supporting studies.

2017-11-01annual_review

Annual review approved October 3, 2017; clarified access-based site-of-service exception for lack of outpatient infusion center within 50 miles or no contracted home infusion agency, and added 7-year long-term follow-up results to references.

2018-02-14interim_review

Interim review approved February 13, 2018 updated hospital-based outpatient coverage from 30 days to 90 days.

2018-11-01annual_review

Annual review approved October 26, 2018 with no changes to the policy statement; references added.

2019-01-01minor_update

Minor update clarifying Consideration of Age information.

2019-06-01interim_review

Interim review approved May 23, 2019 clarifying Nulojix criteria distinctions when used for induction versus maintenance therapy.

2020-01-01annual_review

Annual review approved December 10, 2019 with no changes to policy statement.

2020-12-01annual_review

Annual review approved (12/01/20 entry) with routine updates noted in history.

2023update

Added note that azathioprine may be used for individuals who tried and did not tolerate mycophenolate mofetil (MMF).

2025-10-03operational_clarification

Clarified that Site of Service Medical Necessity criteria can apply to injection drugs (effective October 3, 2025 following 90-day provider notification).

2026-05-25annual_reviewLatest

Annual review approved May 25, 2026 updating the length of initial approval for Nulojix (belatacept) from 6 months to 12 months and adding a site-of-service exception for certain individuals receiving treatment for cytokine release syndrome (CRS).

Material changes in recent updates include operational and authorization modifications: notably, the length of initial approval for Nulojix (belatacept) was updated from 6 months to 12 months, site-of-service exceptions were added (including Alaska fully‑insured member provisions under HB 226 and an exception for certain individuals treated for cytokine release syndrome), and clarification that dosing must follow the product's FDA prescribing information.